Jaguar Health, Inc. (JAGX) - Form 8-K Summary
Business Context and Reporting Period
This Current Report on Form 8-K, dated May 20, 2025, discloses a material definitive agreement entered into by Jaguar Health, Inc. The company, incorporated in Delaware and trading on The Nasdaq Stock Market under the symbol JAGX, announced a registered direct offering and a concurrent private placement. The transaction is expected to close on or about May 22, 2025.
Key Financial Metrics and Transaction Details
- Offering Structure: Registered direct offering of 246,306 shares of Common Stock at $6.09 per share.
- Gross Proceeds: Approximately $1,500,000 before deducting placement agent fees and offering expenses.
- Warrant Issuance: Concurrent private placement of unregistered warrants to purchase up to 492,612 shares of Common Stock (2x the shares sold).
- Warrant Terms: Exercise price of $5.84 per share; immediately exercisable; expire after 24 months or upon a fundamental/liquidation event.
- Placement Agent Fees: H.C. Wainwright & Co., LLC will receive a 7.0% cash fee, a 1.0% management fee, a non-accountable expense allowance of $20,000, and warrants to purchase 14,778 shares (6% of shares sold) at an exercise price of $7.6125.
- Use of Proceeds: Working capital, operating expenses, and repayment of outstanding convertible promissory notes not converted by holders.
Material Changes and Restrictions
The filing does not provide comparative financial data (revenue, profit, cash flow) as this is a transactional report rather than a periodic financial statement. However, the agreement imposes specific restrictions on the Company:
- Issuance Lock-up: Restrictions on issuing Common Stock or equivalents for 15 days following the closing.
- Variable Rate Transaction Restriction: Restrictions on issuances pursuant to variable rate transactions for one year.
- Registration Obligation: The Company must file a registration statement within 30 days of closing for the resale of shares underlying the Common Warrants, with effectiveness required within 60 days (or 90 days if reviewed).
Outlook, Risks, and Management Commentary
Management intends to utilize the net proceeds to bolster liquidity for working capital and to retire specific debt obligations (convertible promissory notes). The transaction was priced at-the-market under Nasdaq rules. The filing notes that the Common Warrants and Wainwright Warrants were offered pursuant to Section 4(a)(2) and Rule 506(b) exemptions and are not registered under the Securities Act at the time of issuance.
Investor Verification Checklist
- Verify the final closing date and actual net proceeds after deducting the 8% total cash fee and other expenses.
- Confirm the specific amount of convertible promissory notes to be repaid with the proceeds.
- Monitor the filing of the registration statement for the warrant shares within the required 30-day window.
- Review the impact of the 246,306 new shares and 492,612 warrant shares on existing shareholder dilution.
- Check for any subsequent filings regarding the exercise of the immediately exercisable warrants.